Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
BörsenkürzelDYAI
Name des UnternehmensDyadic International Inc
IPO-datumNov 05, 2004
CEOMr. Mark A. Emalfarb
Anzahl der mitarbeiter6
WertpapierartOrdinary Share
GeschäftsjahresendeNov 05
Addresse1044 North U.S. Highway One
StadtJUPITER
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl33477
Telefon15617438333
Websitehttps://dyadic.com/
BörsenkürzelDYAI
IPO-datumNov 05, 2004
CEOMr. Mark A. Emalfarb
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten